Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC
NCT05254847
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
65
Enrollment
OTHER
Sponsor class
Conditions
Biliary Tract Cancer
Interventions
DRUG:
Capecitabine combined with lenvatinib and tislelizumab
Sponsor
Fudan University